Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test
dc.contributor.author | Ibrahim, Sherrif F. | |
dc.contributor.author | Kasprzak, Julia M. | |
dc.contributor.author | Hall, Mary A. | |
dc.contributor.author | Fitzgerald, Alison L. | |
dc.contributor.author | Siegel, Jennifer J. | |
dc.contributor.author | Kurley, Sarah J. | |
dc.contributor.author | Covington, Kyle R. | |
dc.contributor.author | Goldberg, Matthew S. | |
dc.contributor.author | Farberg, Aaron S. | |
dc.contributor.author | Trotter, Shannon C. | |
dc.contributor.author | Reed, Kenneth | |
dc.contributor.author | Brodland, David G. | |
dc.contributor.author | Koyfman, Shlomo A. | |
dc.contributor.author | Somani, Ally-Khan | |
dc.contributor.author | Arron, Sarah T. | |
dc.contributor.author | Wysong, Ashley | |
dc.contributor.department | Dermatology, School of Medicine | en_US |
dc.date.accessioned | 2023-02-10T18:56:43Z | |
dc.date.available | 2023-02-10T18:56:43Z | |
dc.date.issued | 2022-03 | |
dc.description.abstract | Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan–Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for Class 1 and ≥50% for Class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Ibrahim, S. F., Kasprzak, J. M., Hall, M. A., Fitzgerald, A. L., Siegel, J. J., Kurley, S. J., Covington, K. R., Goldberg, M. S., Farberg, A. S., Trotter, S. C., Reed, K., Brodland, D. G., Koyfman, S. A., Somani, A.-K., Arron, S. T., & Wysong, A. (2022). Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncology (London, England), 18(7), 833–847. https://doi.org/10.2217/fon-2021-1277 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/31219 | |
dc.language.iso | en | en_US |
dc.publisher | Future Medicine | en_US |
dc.relation.isversionof | 10.2217/fon-2021-1277 | en_US |
dc.relation.journal | Future Oncology | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | * |
dc.source | Publisher | en_US |
dc.subject | clinicopathologic risk factors | en_US |
dc.subject | cutaneous squamous cell carcinoma | en_US |
dc.subject | gene expression profile | en_US |
dc.title | Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test | en_US |
dc.type | Article | en_US |